When people have Alzheimer’s disease, their brains slowly accumulate abnormal clumps of two proteins: amyloid and tau. At ...

Each episode of this journey through a disease state contains both a physician guide and a downloadable/printable patient ...

There exists no ‘amyloid cabal’” in Alzheimer’s research, neurologist Dennis Selkoe writes in response to Charles Piller’s ...

With early diagnosis of Alzheimer's disease comes the possibility of treatment to not only help manage symptoms but also slow ...

In diseases like Parkinson's and Alzheimer's, specific proteins misfold and clump together, forming toxic aggregates that ...

Clinical Dementia Rating (CDR) scores can help doctors tell when people with Alzheimer’s disease experience lower ...

Monoclonal antibodies have emerged as a promising approach in the fight against Alzheimer's disease, offering hope for ...

Both FDA-approved treatments against early AD are antibody-based therapies targeting the recognition and clearance of amyloid plaques in the brain. In other words, they are too big for sneaking ...

Several therapies, including anti-amyloid monoclonal antibodies, have been developed to reduce cerebral amyloid burden that ...

In diseases like Parkinson's and Alzheimer's, specific proteins misfold and clump together, forming toxic aggregates that damage brain ...

New York, February 16 (IANS): A new antibody discovery platform can delve deeper into the mechanisms underlying the processes ...